We conducted a cohort study to examine the association between anticholinergic use and CVEs in a cohort with newly diagnosed COPD. In our study, we found an increased risk of CVE associated with the ...

Review the side-effects of Ipratropium Bromide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

Details concerning the Ipratropium Bromide combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, ...

Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure. Patients taking ipratropium ...

Net revenues of $171.2 million for the three months ended March 31, 2026 GAAP net income of $6.4 million, or $0.14 per share, ... · ACCESS Newswire · Amphastar Pharmaceuticals, Inc. Amphastar ...

Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...

Amphastar Pharmaceuticals, Inc. reported past first-quarter 2026 results with net revenues of US$171.17 million, but net income dropped to US$6.42 million and diluted EPS fell to US$0.14 amid higher ...

Background: Studies have suggested an increased risk of cardiovascular morbidity and mortality associated with the use of ipratropium bromide. We sought to examine the association between ipratropium ...